Aaron S. Mansfield, MD

This video reviews the use of PD-L1 testing in selecting patients for frontline lung cancer treatment with pembrolizumab and examines which patients might not be appropriate for immunotherapy.

The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior.